Is self-sufficiency financially viable and ethically justifiable?--a commercial viewpoint.
Manufacturers of blood products have to maintain the highest possible standards for plasma screening and good manufacturing practices to ensure maximum purity and viral safety. The private sector companies have much experience in implementing and complying with national and international regulations. These requirements involve considerable cost in the areas of (1) plasma collection facilities, (2) research and clinical research, (3) manufacture, and (4) quality control. Total self-sufficiency would mean the loss of many existing resources. An alternative would be a collaboration between the public and private sectors to meet the needs of all patients who require plasma derived products. The current definition of self-sufficiency suggests that it is not financially viable.
Christie
R B
RB
Armour Pharmaceutical Company, Eastbourne, East Sussex, UK.
D001771:Blood Banks / Q000191:economics / Q000592:standards; D001798:Blood Proteins / Q000009:adverse effects / Q000191:economics / Q000600:supply & distribution*; D003132:Commerce; D005060:Europe; D005380:Financing, Government; D005381:Financing, Organized; D017048:Health Care Costs; D006801:Humans; D010949:Plasma; D011786:Quality Control; D012109:Research Support as Topic; D012449:Safety
D001798:Blood Proteins